Elexacaftor Helpful in Cystic Fibrosis Patients Homozygous for F508del Elexacaftor Helpful in Cystic Fibrosis Patients Homozygous for F508del

Elexacaftor, in combination with tezacaftor and ivacaftor, improved outcomes in patients with cystic fibrosis (CF) homozygous for the F508del mutation, in a phase 3 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Related Links:

CONCLUSION: The analysis of the presence of 5T polymporphism in CBAVD patients may add information when predicting the outcome of assisted reproductive techniques. PMID: 31797807 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Behavioral: Guided Grocery Shopping (GGS);   Other: Diet Provision Group Sponsors:   Emory University;   Center for Cystic Fibrosis and Airways Disease Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Interventions:   Other: Autogenic drainage;   Device: SIMEOX + Autogenic drainage Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Nonalcoholic Fatty Liver Disease Interventions:   Behavioral: Guided Grocery Shopping (GGS);   Other: Diet Provision Group Sponsors:   Emory University;   Center for Cystic Fibrosis and Airways Disease Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Cystic Fibrosis pulmonary disease is characterized by chronic airway infections and concomitant non-resolving inflammation that usually leads to respiratory failure within the fourth decade of life. The disease results from patients bearing two mutant copies of the cystic fibrosis transmembrane conductance regulator (CFTR), a channel that transports chloride and bicarbonate [1]. Over 2000 different mutations in CFTR have been identified, and these mutations are associated with varying severity of disease based on how much residual CFTR activity remains.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
AbstractThe contribution of T-cells after lung transplant (LTx) remains controversial with no current consensus of their role concerning chronic lung allograft dysfunction. Using flow cytometry to assess T-cell subsets of bronchoalveolar lavage fluid (BALF) in 16 cystic fibrosis (CF) LTx recipients, we identified a decline in CD4+ T-cell frequency and an increase in CD8+ T-cell frequency in patients who developed severe bronchiolitis obliterans syndrome (BOS) (N = 10) when comparing baseline (6 months post-LTx) and follow-up (most recent bronchoscopy—clinical or surveillance per protocol). Comparin...
Source: Lung - Category: Respiratory Medicine Source Type: research
ConclusionsThe synbiotic had no significant effect on pulmonary and anthropometric outcomes in children with CF. Further studies are necessary to confirm these findings.
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Abstract Airway surface dehydration is a pathological feature of cystic fibrosis (CF) lung disease. CF is caused by mutations in the CF transmembrane conductance regulator (CFTR), a cyclic AMP-regulated Cl- channel controlled in part by the adenosine A2B receptor. An alternative, CFTR-independent mechanism of fluid secretion is regulated by ATP, via the P2Y2 receptor (P2Y2R) that activates Ca2+-regulated Cl- channels (CaCC/TMEM16) and inhibits Na+ absorption. However, due to rapid ATP hydrolysis, steady-state ATP levels in CF airway surface liquid (ASL) are inadequate to maintain P2Y2R-mediated fluid secretion. Th...
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - Category: Cytology Authors: Tags: Am J Physiol Lung Cell Mol Physiol Source Type: research
For the past four years, a research session at the annual European Cystic Fibrosis Society (ECFS) meeting has been co-hosted by The Lancet Respiratory Medicine and the Journal of Cystic Fibrosis. At the 2020 ECFS meeting in June in Lyon, France, we are pleased to announce that the European Respiratory Journal will join this session for the first time.
Source: European Respiratory Journal - Category: Respiratory Medicine Tags: Call for papers Source Type: research
Condition:   Cystic Fibrosis Interventions:   Drug: ELX/TEZ/IVA;   Drug: IVA Sponsor:   Vertex Pharmaceuticals Incorporated Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cystic Fibrosis | Health